Pegfilgrastim
- Generic Name
- Pegfilgrastim
- Brand Names
- Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 208265-92-3
- Unique Ingredient Identifier
- 3A58010674
- Background
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...
- Indication
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...
- Associated Conditions
- Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
- Associated Therapies
- -
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
- Conditions
- Interventions
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 92
- Registration Number
- NCT00472849
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-07-01
- Lead Sponsor
- Armando Santoro, MD
- Target Recruit Count
- 80
- Registration Number
- NCT00410696
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milan, Italy
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- George Albert Fisher
- Target Recruit Count
- 21
- Registration Number
- NCT00404066
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Santa Clara Valley Medical Center, San Jose, California, United States
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 197
- Registration Number
- NCT00394251
Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients
- Conditions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT00364468
- Locations
- 🇯🇵
Kyusyu region, Fukuoka, Nagasaki, Japan
🇯🇵Tokai region, Aichi, Japan
🇯🇵Kanto region, Gunma, Saitama, Tokyo, Kanagawa, Japan
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT00334815
- Locations
- 🇺🇸
Ballad Health Cancer Care - Norton, Norton, Virginia, United States
🇺🇸Providence Hospital, Mobile, Alabama, United States
🇺🇸Saint Bernards Regional Medical Center, Jonesboro, Arkansas, United States
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
- Conditions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2006-09-26
- Lead Sponsor
- The Alvin and Lois Lapidus Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00333008
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Northwest Hospital Center, Randallstown, Maryland, United States
Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 14
- Registration Number
- NCT00306111
- Locations
- 🇩🇪
Dept. of Medicine 2, University of Tuebingen, Tuebingen, BW, Germany
Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim
- Conditions
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00280787
- Locations
- 🇺🇸
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 920
- Registration Number
- NCT00151242
- Locations
- 🇩🇪
Clinical Center of Hematology and Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany
🇦🇹Department of Hematology/Oncology, University Hospital Innsbruck, Innsbruck, Austria
🇩🇪Department of Hematology and Oncology, Hospital Essen Süd, Ev. Hospital of Essen-Werden, Essen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.